The Cells of the Islets of Langerhans

Gabriela Da Silva Xavier 1,2

1 Section of Functional Genomics and Cell Biology, Department of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK; g.dasilva-xavier@imperial.ac.uk or G.DaSilvaXavier@bham.ac.uk; Tel.: +44-(0)207-594-3358
2 Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Edgbaston B15 2TT, UK

Received: 2 January 2018; Accepted: 7 March 2018; Published: 12 March 2018

Abstract: Islets of Langerhans are islands of endocrine cells scattered throughout the pancreas. A number of new studies have pointed to the potential for conversion of non-β islet cells in to insulin-producing β-cells to replenish β-cell mass as a means to treat diabetes. Understanding normal islet cell mass and function is important to help advance such treatment modalities: what should be the target islet/β-cell mass, does islet architecture matter to energy homeostasis, and what may happen if we lose a particular population of islet cells in favour of β-cells? These are all questions to which we will need answers for islet replacement therapy by transdifferentiation of non-β islet cells to be a reality in humans. We know a fair amount about the biology of β-cells but not quite as much about the other islet cell types. Until recently, we have not had a good grasp of islet mass and distribution in the human pancreas. In this review, we will look at current data on islet cells, focussing more on non-β cells, and on human pancreatic islet mass and distribution.

Keywords: islets of Langerhans; insulin; glucagon; somatostatin; pancreatic polypeptide; ghrelin; pancreas; diabetes; endocrine

1. Introduction

The islands or (more commonly) islets of Langerhans, first described by their namesake- Paul Langerhans- in 1969, are islands of mixed populations of endocrine cells that are scattered in the parenchyma of the pancreas. Islets of Langerhans have been much studied in the context of diabetes due to the hormones produced and secreted from the cells which form these micro-organs, which are involved in the regulation of glucose homeostasis. The discovery of insulin, and the demonstration that it can lower blood glucose in dogs, by Frederick Banting and Charles Best in 1921, and its subsequent development for clinical use, in collaboration with John Macleod and James Collip, led to the award of the Nobel Prize in Physiology or Medicine to Banting and Macleod in 1923. Since then, the biology of the insulin producing β-cells in the islet came under much scrutiny as the loss of β-cell function, hence the loss of insulin, was associated with diabetes. Initially, much more associated with type 1 diabetes, which is characterised by the loss of β-cell mass due to autoimmune attack of this cell type, loss of functional β-cell mass is now also associated with type 2 diabetes (T2D).

There are multiple developmental cues for islet formation ranging from external cues such as nutritional status (i.e., the maternal nutritional state) to signals from the developing foetus e.g., from the central nervous system [1]. Replenishment of β-cell mass following the loss of significant β-cell mass (circa 90%) in mice has been shown to lead to activation of β-cell duplication [2,3]. Recuperation of β-cell mass following >90% loss of β-cell mass was shown to be via transdifferentiation of other islet cells, e.g., α-cells [4] and δ-cells [5], into β-cells. Data from the literature indicate that whilst loss of pancreatic β-cell mass may lead to disease, there is little or no effect on physiology from near complete loss of α-cell mass, responsible for secretion of glucagon (the counter hormone to insulin) in rodents [6]. With the advent of the possibility to switch islet cell identity as a means to alter islet cell
mass as treatment for diabetes [4,5,7,8], it is perhaps timely to review current information on islet cell mass and the function of the different islet cell types.

2. Islet Distribution in the Pancreas: Structure, Size, Location

The total number of islets in a human pancreas has been estimated to be between 3.2 and 14.8 million, with a total islet volume of 0.5 to 2.0 cm³ [9–14]. The cellular composition and architecture of pancreatic islets differ between and within species [15,16]. The inter-species differences have previously been shown to correlate with functional differences [17]. Human islets consist of circa 30% glucagon-producing α-cells, circa 60% insulin producing β-cells, with the remainder circa 10% made up of δ-cells (somatostatin-producing), γ- or PP cells (pancreatic polypeptide-producing), and ε-cells (ghrelin-producing) [9,17–20], with these endocrine cells randomly distributed throughout the islet [15–17]. Rodent islets are widely used in biomedical research, and have a different architecture with a core of β-cells surrounded by the other endocrine cell types [16,21–23].

Recently, Ionescu–Tirgoviste and colleagues [9] performed a careful evaluation of islet characteristics from a healthy human pancreas by analysing pancreatic sections to produce a three-dimensional islet distribution map. The study revealed that the human pancreas contains on average 3.2 million islets, with a mean islet diameter of 108.92 µm (±6.27 µm), and a mean islet volume of 0.00069 µL (±0.00011 µL) [9]. The majority of islets (~66%) have a surface area of between 1000 and 10,000 µm². Approximately 24% and 9% of islets had a surface area of more than 100,000 µm² and less than 1000 µm², respectively. The islets appear to have a threshold surface area of about 100,000 µm², where “islets” that have apparently larger surface area than the threshold were made up of clusters of islets [9]. The smaller islets tended to cluster around blood vessels [9]. When islet surface area and distribution were averaged over pancreas section area, Ionescu-Tirgoviste and colleagues concluded that there was a uniform scattering of islets in the body of the pancreas, with the islets adopting an overall spherical structure [9]. This is in contrast to previous reports indicating an uneven distribution of islets in human [24] and rodent pancreas [21,25–32], although the differences may be due to differences in the methodologies used for estimating β-cell mass.

Islet mass and distribution in the pancreas may be an important consideration in light of the known metabolic consequences of pancreatectomy, where patients suffer a sudden loss of islet cell mass from surgical resection of the pancreas. Patients that have undergone a 50% (partial) pancreatectomy have reduced insulin secretion (circa 50%) but the region of pancreas that is removed was reported to have different metabolic impact [33]. Thus, removal of the pancreatic tail led to post-operative elevated fasting glucose and post-challenge glycaemia, whilst removal of the pancreatic head caused an improvement in oral glucose tolerance [33]. Earlier studies involving the loss of the pancreatic tail in human subjects also reported lowered insulin secretion and glucose tolerance in patients one year after partial pancreatectomy [34]. Intriguingly, the data from the pancreatectomy studies, together with Ionescu-Tirgoviste and colleagues’ report [9] that there was a uniform scattering of islets in the body of the pancreas, may imply that there are functional differences between the islets in the head and the tail of the pancreas. Thus, it would appear, not all islets are the same and there may be differences in the islet population in the head vs the tail of the pancreas. Such considerations are important beyond academic curiosity. The head and the tail of the pancreas have different developmental origins: the head of the pancreas is formed from the dorsal and ventral pancreatic bud, and the body and tail of the pancreas are formed from the ventral pancreatic bud [35]. Studies in rodents have previously shown that islets originating from the dorsal pancreatic bud had greater capacity to secrete and synthetise insulin than islets of ventral bud origins [26–29], perhaps hinting at potential programming differences during development in islets (reviewed extensively in [36]) in relation to their function and adaptive responses in adult life. This in turn may have an impact on the therapeutic strategies that may be pliable to increase functional β-cell mass in vivo (see Section 4 below) [26–29,33,35–38].
3. α-Cell

It would be fair to say that a lot less is known about the glucagon producing α-cell than the insulin producing β-cell. Glucagon is the counter hormone to insulin, and is typical of the fasted state. The concerted regulation of glucagon and insulin secretion is a major mechanism for the regulation of blood glucose. The major function of the counter-regulatory response is the prevention of hypoglycaemia, a response that is impaired in diabetes [37,38]. The importance of glucagon to the pathophysiology of T2D was first highlighted by Unger and colleagues in the bihormonal hypothesis which states that both hypoinsulinaemia and hyperglucagonaemia contributes to hyperglycaemia in T2D [39,40]. Thus, in T2D, α-cells display elevated glucagon secretion, enhanced glucagon secretion in response to amino acids, and ineffective suppression of glucagon secretion by high plasma glucose [41].

The importance of the regulation of α-cell function in the pathophysiology of T2D is currently the subject of intense research [42–44].

Glucagon secretion is regulated by both α-cell intrinsic and paracrine mechanisms. For example, it has been proposed that hyperglucagonaemia in T2D may be a result of the loss of intrinsic regulatory mechanism by glucose and amino acids, and extrinsic regulation by insulin and zinc, in the α-cells [41,45–53]. However, the loss of sensitivity to nutrients, insulin and zinc as mechanisms for hyperglucagonaemia have all been disputed [54–58]. The gut hormones—Glucagon-Like Peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP)—have been proposed to be important in the regulation of glucagon secretion [59–66]. Additionally, there is evidence to suggest that GLP-1 can be produced in human islets, possibly in α-cells [67]. Somatostatin, secreted by pancreatic δ-cells, suppresses glucagon secretion [68–70]; it has been proposed that the inhibitory effect of GLP-1 on glucagon secretion [71] is effected indirectly via the stimulation of somatostatin secretion by GLP-1 [72].

The islets of Langerhans are innervated and subject to the regulation by the sympathetic and parasympathetic system such that glucagon secretion is stimulated in hypoglycaemia [73–76]. One characteristic of T2D is the progressive loss of the stimulation of glucagon and counter-regulatory hormones in patients treated with insulin [77,78]. Moreover, it has been reported that sympathetic innervation during pancreatic development is required for establishment of islet architecture and function [1], with the localisation of non-β cells a primary determinant of islet architecture [16,22,75,79]. Thus, the loss of non-β cell e.g. for the transdifferentiation into β-cells, may lead to the loss overall islet architecture, with implications on islet function.

In summary, the current evidence indicates that the intrinsic, nervous and paracrine regulation of glucagon secretion are not mutually exclusive, and likely act in concert [43,80].

Recently, Collombat and colleagues have demonstrated the potential to transdifferentiate endogenous α-cells in to β-like cells to replenish β-cell function through the administration of gamma aminobutyric acid (GABA) [7,8]. Furthermore, the authors showed that there was a continuous replenishment of glucagon-positive cells indicating that GABA treatment, not only induces transdifferentiation of α-cells in to β-like cells, but also maintains an α-cell pool [8]. This is important as it suggests that this treatment may be able to maintain the overall proportion of islet cell types (see Figure 1), although it is currently clear whether this will have effects on islet architecture and function in the long term. Nevertheless, this is a particularly intriguing finding as, whilst it has previously been demonstrated that near complete ablation of α-cells in rodents had little physiological effect [6], partial pancreatectomy in humans have been shown to lead to enhanced responsiveness to glucagon [81], and to secretion of glucagon from extra-pancreatic sites [82,83], both of which leads to altered glucose handling. Thus, although it is useful to be able to make β-like cells from α-cells, maintaining an α-cell population may also be important for the maintenance of glucose homeostasis in humans.

In any cell (re)programming protocol, it is important to have a grasp of the identities/characteristics of the starting cell and the destination cell. The current state of the art is likely to act as a further catalyst for studies in to the α-cell as a result. For example, recent studies focussed on identifying β-cells based
on expression profiles of protein-encoding genes and non-coding RNAs, are now also paralleled in α-cells [84–105].

Figure 1. Schematic diagram showing the interdependency of islet cells. Evidence in the literature points to the possibility of the transdifferentiation (solid black arrows) of α-cells (red circle) via stimulation by gamma aminobutyric acid (GABA), and δ-cells (yellow circle) into insulin-containing β (like)-cells (blue circle). It is currently unclear whether the replenishment of β-cells from the transdifferentiation of α-cells is able to replace hub β-cells (light blue circle) which influence (yellow arrows) the function of other β-cells. Somatostatin, released from δ-cells, can inhibit the release of glucagon, insulin, and pancreatic polypeptide from α-, β-, and PP cells (green circle), respectively. Pancreatic polypeptide, released from PP cells, can inhibit the release of glucagon. Ghrelin, released from ghrelin-positive islet cells (purple circle), can inhibit insulin and somatostatin secretion.

4. β-Cell

The β-cell is the most studied of the islet cell types and has been written about copiously [106–111], so it would be superfluous to elaborate too much here. There are important differences between mouse and human β-cells which need to be considered in the design of therapeutic interventions for increasing functional β-cell mass [106].

What is a β-cell? Simplistically, it is a cell that makes insulin that is able to secrete insulin in response to a glucose challenge. Insulin is packaged into secretory granules at concentrations of circa 100 mM [112,113] as a complex with zinc, and released in response to high glucose (and other nutrient) concentrations [113] and stimulation by neurotransmitters that are released in response to food [114]. Insulin secretion is also enhanced by the presence of incretin hormones [114]. Somatostatin, which is secreted by neighbouring δ-cells, inhibit insulin secretion [115], as do epinephrine [116,117], galanin [118], ghrelin [119], leptin [120] and zinc ions [121]. Glucose metabolism in the β-cell differs from other cell types in that the presence of low affinity, high transport capacity glucose transporter(s) (GLUT1 and 2 in humans, Glut2 in mice) [122–125], and the low affinity hexokinase-glucokinase (GCK) [126,127] results in β-cell glucose metabolism being controlled by substrate availability. Glycolysis and mitochondrial oxidation are closely coupled, due to the lack of expression of “disallowed genes” such as lactate dehydrogenase (LDH) and the monocarboxylate transporter (MCT1) [128]. This coupling is disrupted in islets of Langerhans from type 2 diabetic donors [127,129,130], with concomitant expression of disallowed genes such as LDH and MCT1.
Unsurprisingly there is currently much attention on the identity of the islet cell types, with the focus predominantly on the β-cell, especially in the context of coding and non-coding RNA (as mentioned in the Section 3), which may be involved in the regulation of the expression these disallowed or β-cell specific genes.

ATP production leads to closure of the ATP sensitive K⁺ channel (K<sub>ATP</sub>) channel on the cell surface; the subsequent membrane depolarization leads to opening of voltage-gated L-type calcium channels, influx of calcium and the release of insulin (detailed mechanisms reviewed in [106]).

Interestingly, studies looking at β-cell regeneration in humans following partial pancreatectomy demonstrated an increase in β-cell function [131] but not β-cell mass [132]. Additionally, the same cohort of patients that had previously exhibited post-operative elevated fasting glucose and post-challenge glycaemia [33], showed amelioration of both parameters circa 3 years after pancreatectomy due to increased β-cell function [131]. Taken together with data from Ionescu-Tirgoviste and colleagues [9], which demonstrate that islet distribution is even throughout the human pancreas, the ability to increase function may not be dependent on the location of the β-cell in the pancreas. This compensatory increase in β-cell function is also seen in hyper-functional islets from obese individuals [113,133–138] which exhibit a two- to three-fold increase in insulin secretory capacity vs. lean individuals [139,140]. The obesity model also offers a contrary view to human β-cell mass plasticity vs pancreatectomy model: there is convincing data from various sources indicating that β-cell regeneration may occur in pancreases from obese subjects [135,140–146]. Add to this the potential to transdifferentiate α-cells to β-cells [8], and the potential of transplantation of human pluripotent stem cell-derived β-like cells [147], the future seems bright for restoring β-cell mass. However, one recent development may throw a spanner in the works. There is significant heterogeneity in β-cells within an islet which suggests that the structure of the islet—the connections between cells and the spatial arrangement of islet cells—may be important for the regulation of islet function [110,148,149].

δ-cells have been reported to transdifferentiate into β-cells in acute depletion of β-cell mass [5]. The transcription factor Pax4 is involved in the development of both β- and δ-cells during pancreatic
specification [169]. Recently it was shown that mis-expression Pax4 in α-cells leads to conversion to β-like cells with no evidence for δ-cell like conversion [7]. It has been shown that the δ-cell fate is maintained by the Hhex gene [170]; loss of Hhex led to disrupted paracrine regulation of insulin secretion, which may potentially contribute to T2D [170,171]. Similarly, as δ-cells also regulate α-cells, loss of δ-cell mass due to transdifferentiation into β-cells may lead to dysregulated glucagon secretion. In short, the current evidence does not support transcription of δ-cells to β-cells as a viable means to replenish β-cell mass.

6. PP Cell

Pancreatic polypeptide containing cells, also called PP cells or F-cells [172–176], make up 1–2% of the islet cell population [177–179]. PP cells are more concentrated in the head of the pancreas [180,181], where the cells are found to occupy the outer mantle of rodent islets or lining the capillaries in human islets [79]. Post-prandial pancreatic polypeptide release is regulated by vagal and enteric nervous input [182–185], and is responsive to arginine but not glucose stimulation [186]. Pancreatic polypeptide has been shown to be an inhibitor of glucagon release at low glucose [187] (see Figure 1). The major function of PP appears to be that of a satiety hormone (reviewed in [188]).

7. Ghrelin-Positive and Other Islet Cell Types

A further three types of islet cells have been described in the literature. These cells contain ghrelin [189,190], serotonin (enterochromaffin cells) [191,192], gastrin (G-cells) [174,193], and small granules of unknown content (P/D1-cells) [174,191,194–197]. Of these the ghrelin positive cells have recently attracted the most interest. Ghrelin-positive cells are mainly found in the gut [195,198–201]. Ghrelin-positive cells are also found in the islet, accounting for circa 10% and 1% of islet cell content in foetal and adult islets, respectively [119,189,190,195]. It has been suggested that ghrelin positive cells in the islets are in fact the P/D1 cells, which were described as containing an unknown hormone, as the two cell types share a lot of ultrastructural and distribution similarities [119]. The developmental programme for ghrelin positive cells appear to be different between human, mouse and rat (reviewed in [119]), and thus data on developmental pathways for ghrelin cells elucidated in mice (e.g., [202]) may not apply to humans. Ghrelin is increased in fasting [203–205]; plasma ghrelin content has a reciprocal relationship with plasma insulin content [206,207], and has been shown to be an inhibitor of insulin secretion in human and rodents [208–213]. Ghrelin may also be a regulator of glucagon, PP and somatostatin release [210,214,215].

8. Conclusions

The cells in the islets have distinct regulatory function and operate within a complex regulatory network invoking paracrine and neuronal control of energy homeostasis. There are differences in islet architecture and distribution between human and experimental models, which may have an impact on islet function and energy homeostasis. Recent reports have indicated islet cells are plastic and that it may be possible to convert non-β islet cells into β-cells to replenish β-cell mass and function [4,5,7,8]. This knowledge may be important for the development of treatment strategies for diabetes, but will require careful evaluation of the impact of the loss of a particular non-β islet endocrine cell type on energy homeostasis.

Acknowledgments: Gabriela da Silva Xavier thanks Diabetes UK, the MRC, and the European Foundation for the Study of Diabetes for funding in support of her research activities.

Conflicts of Interest: The author declares no conflict of interest.
References

1. Borden, P.; Houtz, J.; Leach, S.D.; Kuruvilla, R. Sympathetic innervation during development is necessary for pancreatic islet architecture and functional maturation. Cell Rep. 2013, 4, 287–301. [CrossRef] [PubMed]

2. Dor, Y.; Brown, J.; Martineau, O.I.; Melton, D.A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004, 429, 41–46. [CrossRef] [PubMed]

3. Cano, D.A.; Rulifson, I.C.; Heiser, P.W.; Swigart, L.B.; Pelengaris, S.; German, M.; Evan, G.I.; Bluestone, J.A.; Hebrok, M. Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes 2008, 57, 958–966. [CrossRef] [PubMed]

4. Thorel, F.; Nepote, V.; Avril, I.; Kohno, K.; Desgraz, R.; Chera, S.; Herrera, P.L. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 2010, 464, 1149–1154. [CrossRef] [PubMed]

5. Chera, S.; Baronnier, D.; Ghila, L.; Cigliola, V.; Jensen, J.N.; Gu, G.; Furuyama, K.; Thorel, F.; Gribble, F.M.; Reimann, F.; et al. Diabetes recovery by age-dependent conversion of pancreatic delta-cells into insulin producers. Nature 2014, 514, 503–507. [CrossRef] [PubMed]

6. Thorel, F.; Damond, N.; Chera, S.; Wiederkher, A.; Thorens, B.; Meda, P.; Wollheim, C.B.; Herrera, P.L. Normal glucagon signaling and beta-cell function after near-total alpha-cell ablation in adult mice. Diabetes 2011, 60, 2872–2882. [CrossRef] [PubMed]

7. Napolitano, T.; Avolio, F.; Courtney, M.; Vieira, A.; Druelle, N.; Ben-Othman, N.; Hadzic, B.; Navarro, S.; Collombat, P. Pax4 acts as a key player in pancreas development and plasticity. Semin. Cell Dev. Biol. 2015, 44, 107–114. [CrossRef] [PubMed]

8. Ben-Othman, N.; Vieira, A.; Courtney, M.; Record, F.; Gjernes, E.; Avolio, F.; Hadzic, B.; Druelle, N.; Napolitano, T.; Navarro-Sanz, S.; et al. Long-term gaba administration induces alpha cell-mediated beta-like cell neogenesis. Cell 2017, 168, 73–85. [CrossRef] [PubMed]

9. Ionescu-Tirgoviste, C.; Gagniuc, P.A.; Gubceac, E.; Mardare, L.; Popescu, I.; Dima, S.; Militaru, M. A 3D map of the islet routes throughout the healthy human pancreas. Sci. Rep. 2015, 5, 14634. [CrossRef] [PubMed]

10. Saito, K.; Iwama, N.; Takahashi, T. Morphometrical analysis on topographical difference in size distribution, number and volume of islets in the human pancreas. Tohoku J. Exp. Med. 1978, 124, 177–186. [CrossRef] [PubMed]

11. Hellman, B. Actual distribution of the number and volume of the islets of langerhans in different size classes in non-diabetic humans of varying ages. Nature 1959, 184 (Suppl. 19), 1498–1499. [CrossRef] [PubMed]

12. Hellman, B. The numerical distribution of the islets of langerhans at different ages of the rat. Acta Endocrinol. 1959, 32, 63–77. [CrossRef] [PubMed]

13. Hellman, B. The volumetric distribution of the pancreatic islet tissue in young and old rats. Acta Endocrinol. 1959, 39, 91–106. [CrossRef] [PubMed]

14. Hellman, B. The frequency distribution of the number and volume of the islets langerhans in man. I. Studies on non-diabetic adults. Acta Soc. Med. Ups. 1959, 64, 432–460. [PubMed]

15. Kim, A.; Miller, K.; Jo, J.; Kilimnik, G.; Wojcik, P.; Hara, M. Islet architecture: A comparative study. Islets 2009, 1, 129–136. [CrossRef] [PubMed]

16. Steiner, D.J.; Kim, A.; Miller, K.; Hara, M. Pancreatic islet plasticity: Interspecies comparison of islet architecture and composition. Islets 2010, 2, 135–145. [CrossRef] [PubMed]

17. Cabrera, O.; Berman, D.M.; Kenyon, N.S.; Ricordi, C.; Berggren, P.O.; Caicedo, A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc. Natl. Acad. Sci. USA 2006, 103, 2334–2339. [CrossRef] [PubMed]

18. Brissova, M.; Fowler, M.J.; Nicholson, W.E.; Chu, A.; Hirshberg, B.; Harlan, D.M.; Powers, A.C. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J. Histochem. Cytochem. 2005, 53, 1087–1097. [CrossRef] [PubMed]

19. Orci, L.; Baetens, D.; Ravazzola, M.; Stefan, Y.; Malaisse-Lagae, F. Pancreatic polypeptide and glucagon: Non-random distribution in pancreatic islets. Life Sci. 1976, 19, 1811–1815. [CrossRef] [PubMed]

20. Ichii, H.; Inverardi, L.; Pileggi, A.; Molano, R.D.; Cabrera, O.; Caicedo, A.; Messinger, S.; Kuroda, Y.; Berggren, P.O.; Ricordi, C. A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am. J. Transplant. 2005, 5, 1635–1645. [CrossRef] [PubMed]

21. Elayat, A.A.; el-Naggar, M.M.; Tahir, M. An immunocytochemical and morphometric study of the rat pancreatic islets. J. Anat. 1995, 186 Pt 3, 629–637. [PubMed]
Gittes, G.K. Developmental biology of the pancreas: A comprehensive review. *Lancet* 1975, 2, 1243–1244. [CrossRef]

Samols, E.; Bonner-Weir, S.; Weir, G.C. Intra-islet insulin-glucagon-somatostatin relationships. *Clin. Endocrinol. Metab.* 1986, 15, 33–58. [CrossRef]

Wang, X.; Misawa, R.; Zielinski, M.C.; Cowen, P.; Jo, J.; Periwal, V.; Ricordi, C.; Khan, A.; Szust, J.; Shen, J.; et al. Regional differences in islet distribution in the human pancreas--preferential beta-cell loss in the head region in patients with type 2 diabetes. *PloS ONE* 2013, 8, e67454. [CrossRef] [PubMed]

Baetens, D.; Malaisse-Lagae, F.; Perrelet, A.; Orci, L. Endocrine pancreas: Three-dimensional reconstruction shows two types of islets of langerhans. *Science* 1979, 206, 1323–1325. [CrossRef] [PubMed]

Trimble, E.R.; Halban, P.A.; Wollheim, C.B.; Renold, A.E. Functional differences between rat islets of ventral and dorsal pancreatic origin. *J. Clin. Investig.* 1982, 69, 405–413. [CrossRef] [PubMed]

Trimble, E.R.; Renold, A.E. Ventral and dorsal areas of rat pancreas: Islet hormone content and secretion. *Am. J. Physiol.* 1981, 240, E422–E427. [CrossRef] [PubMed]

Leclercq-Meyer, V.; Marchand, J.; Malaisse, W.J. Insulin and glucagon release from the ventral and dorsal parts of the perfused pancreas of the rat. Effects of glucose, arginine, glucagon and carbamylcholine. *Horm. Res.* 1985, 21, 19–32. [CrossRef] [PubMed]

Tasaka, Y.; Matsumoto, H.; Inoue, Y.; Hirata, Y. Contents and secretion of glucagon and insulin in rat pancreatic islets from the viewpoint of their localization in pancreas. *Tohoku J. Exp. Med.* 1989, 159, 123–130. [CrossRef] [PubMed]

Yukawa, M.; Takeuchi, T.; Watanabe, T.; Kitamura, S. Proportions of various endocrine cells in the pancreatic islets of wood mice (*Apodemus speciosus*). *Anat. Histol. Embryol.* 1999, 28, 13–16. [CrossRef] [PubMed]

Aguayo-Mazzucato, C.; Sanchez-Soto, C.; Godinez-Puig, V.; Gutierrez-Ospina, G.; Hiriart, M. Restructuring of pancreatic islets and insulin secretion in a postnatal critical window. *PLoS ONE* 2006, 1, e35. [CrossRef] [PubMed]

Hornblad, A.; Cheddad, A.; Ahlgren, U. An improved protocol for optical projection tomography imaging reveals lobular heterogeneities in pancreatic islet and beta-cell mass distribution. *Islets* 2011, 3, 204–208. [CrossRef] [PubMed]

Menge, B.A.; Schrader, H.; Breuer, T.G.; Dabrowski, Y.; Uhl, W.; Schmidt, W.E.; Meier, J.J. Metabolic consequences of a 50% partial pancreatectomy in humans. *Diabetologia* 2009, 52, 306–317. [CrossRef] [PubMed]

Kendall, D.M.; Sutherland, D.E.; Najarian, J.S.; Goetz, F.C.; Robertson, R.P. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. *N. Engl. J. Med.* 1990, 322, 898–903. [CrossRef] [PubMed]

Pandol, S.J. *The Exocrine Pancreas*; Morgan & Claypool Life Sciences: San Rafael, CA, USA, 2010.

Gittes, G.K. Developmental biology of the pancreas: A comprehensive review. *Dev. Biol.* 2009, 326, 4–35. [CrossRef] [PubMed]

Gerich, J.E. Lilly lecture 1988. Glucose counterregulation and its impact on diabetes mellitus. *Diabetes* 1988, 37, 1608–1617. [CrossRef] [PubMed]

Gerich, J.E.; Campbell, P.J. Overview of counterregulation and its abnormalities in diabetes mellitus and other conditions. *Diabetes Metab. Rev.* 1988, 4, 93–111. [CrossRef] [PubMed]

Unger, R.H.; Orci, L. The essential role of glucagon in the pathogenesis of diabetes mellitus. *Lancet* 1975, 1, 14–16. [CrossRef]

Cryer, P.E. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. *Endocrinology* 2012, 153, 1039–1048. [CrossRef] [PubMed]

Dunning, B.E.; Gerich, J.E. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. *Endocr. Rev.* 2007, 28, 253–283. [CrossRef] [PubMed]

Unger, R.H.; Orci, L. Glucagon and the a cell: Physiology and pathophysiology (first two parts). *N. Engl. J. Med.* 1981, 304, 1518–1524. [CrossRef] [PubMed]

Gromada, J.; Franklin, I.; Wollheim, C.B. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. *Endocr. Rev.* 2007, 28, 84–116. [CrossRef] [PubMed]

Lee, Y.; Wang, M.Y.; Du, X.Q.; Charron, M.J.; Unger, R.H. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. *Diabetes* 2011, 60, 391–397. [CrossRef] [PubMed]
45. Dunning, B.E.; Foley, J.E.; Ahren, B. Alpha cell function in health and disease: Influence of glucagon-like peptide-1. *Diabetologia* 2005, 48, 1700–1713. [CrossRef] [PubMed]

46. Gylfe, E. Glucose control of glucagon secretion—there’s a brand-new gimmick every year’. *Ups. J. Med. Sci.* 2016, 121, 120–132. [CrossRef] [PubMed]

47. Gylfe, E.; Gilon, P. Glucose regulation of glucagon secretion. *Diabetes Res. Clin. Pract.* 2014, 103, 1–10. [CrossRef] [PubMed]

48. Ishihara, H.; Maechler, P.; Gjfnovici, A.; Herrera, P.L.; Wollheim, C.B. Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. *Nat. Cell Biol.* 2003, 5, 330–335. [CrossRef] [PubMed]

49. Berggren, P.O.; Ostenson, C.G.; Petersson, B.; Hellman, B. Evidence for divergent glucose effects on calcium metabolism in pancreatic beta- and alpha 2-cells. *Endocrinology* 1979, 105, 1463–1468. [CrossRef] [PubMed]

50. Ostenson, C.G. Regulation of glucagon release: Effects of insulin on the pancreatic a2-cell of the guinea pig. *Diabetologia* 1979, 17, 325–330. [CrossRef] [PubMed]

51. Pipeleers, D.G.; Schuit, F.C.; Van Schravendijk, C.F.; Van de Winkel, M. Interplay of nutrients and hormones in the regulation of glucagon release. *Endocrinology* 1985, 117, 817–823. [CrossRef] [PubMed]

52. Walker, J.N.; Ramacheyya, R.; Zhang, Q.; Johnson, P.R.; Braun, M.; Rorsman, P. Regulation of glucagon secretion by glucose: Paracrine, intrinsic or both? *Diabetes Obes. Metab.* 2011, 13 (Suppl. 1), 95–105. [CrossRef] [PubMed]

53. Zhou, H.; Zhang, T.; Harmon, J.S.; Bryan, J.; Robertson, R.P. Zinc, not insulin, regulates the rat alpha-cell response to hypoglycemia in vivo. *Diabetes* 2007, 56, 1107–1112. [CrossRef] [PubMed]

54. Knop, F.K.; Vilsboll, T.; Madshbad, S.; Holst, J.J.; Krarup, T. Inappropriate suppression of glucagon during ogtt but not during isoglycaemic i.v. Glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. *Diabetologia* 2007, 50, 797–805. [CrossRef] [PubMed]

55. Meier, J.J. The contribution of incretin hormones to the pathogenesis of type 2 diabetes. *Best Pract. Res. Clin. Endocrinol. Metab.* 2009, 23, 433–441. [CrossRef] [PubMed]

56. Meier, J.J.; Deacon, C.F.; Schmidt, W.E.; Holst, J.J.; Nauck, M.A. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. *Diabetologia* 2007, 50, 806–813. [CrossRef] [PubMed]

57. Nicolson, T.J.; Bellomo, E.A.; Wijesekara, N.; Loder, M.K.; Baldwin, J.M.; Gyulkhandanyan, A.V.; Koshkin, V.; Tarasov, A.I.; Carzaniga, R.; Kronenberger, K.; et al. Insulin storage and glucose homeostasis in mice null for the granule zinc transporter znit8 and studies of the type 2 diabetes-associated variants. *Diabetes* 2009, 58, 2070–2083. [CrossRef] [PubMed]

58. Ravier, M.A.; Rutter, G.A. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. *Diabetes* 2005, 54, 1789–1797. [CrossRef] [PubMed]

59. Santeusanio, F.; Faloona, G.R.; Unger, R.H. Suppressive effect of secretin upon pancreatic alpha cell function. *J. Clin. Investig.* 1972, 51, 1743–1749. [CrossRef] [PubMed]

60. Rushakoff, R.J.; Goldfine, I.D.; Carter, J.D.; Liddle, R.A. Physiological concentrations of cholecystokinin worsen post prandial hyperglycemia in type 2 diabetes. *Am. J. Physiol. Endocrinol. Metab.* 2011, 300, E1038–E1046. [CrossRef] [PubMed]

61. De Heer, J.; Pedersen, J.; Orskov, C.; Holst, J.J. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. *Diabetologia* 2007, 50, 2135–2142. [CrossRef] [PubMed]

62. Nauck, M.A.; Weber, I.; Bach, I.; Richter, S.; Orskov, C.; Holst, J.J.; Schniegel, W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. *Diabet. Med.* 1998, 15, 937–945. [CrossRef]

63. Chia, C.W.; Carlson, O.D.; Kim, W.; Shin, Y.K.; Charles, C.P.; Kim, H.S.; Melvin, D.L.; Egan, J.M. Exogenous glucose-dependent insulinotropin polypeptide polypeptide worsens post prandial hyperglycemia in type 2 diabetes. *Diabetes* 2009, 58, 1342–1349. [CrossRef] [PubMed]

64. Lund, A.; Vilsboll, T.; Bagger, J.I.; Holst, J.J.; Knop, F.K. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. *Am. J. Physiol. Endocrinol. Metab.* 2011, 300, E1038–E1046. [CrossRef] [PubMed]

65. Lund, A.; Bagger, J.I.; Christensen, M.; Knop, F.K.; Vilsboll, T. Glucagon and type 2 diabetes: The return of the alpha cell. *Curr. Diabetes Rep.* 2014, 14, 555. [CrossRef] [PubMed]
66. De Marinis, Y.Z.; Salehi, A.; Ward, C.E.; Zhang, Q.; Abdulkader, F.; Bengtsson, M.; Braha, O.; Braun, M.; Ramacheya, R.; Amisten, S.; et al. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca$^{2+}$ channel-dependent exocytosis. Cell Metab. 2010, 11, 543–553. [CrossRef] [PubMed]

67. Marchetti, P.; Lupi, R.; Bugliani, M.; Kirkpatrick, C.L.; Sebastiani, G.; Grieco, F.A.; Del Guerra, S.; D’Aleo, V.; Piro, S.; Marselli, L.; et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 2012, 55, 3262–3272. [CrossRef] [PubMed]

68. Luft, R.; Endric, S.; Hokfelt, T. Somatostatin—Both hormone and neurotransmitter? Diabetologia 1978, 14, 1–13. [CrossRef] [PubMed]

69. Klaff, L.J.; Taborsky, G.J., Jr. Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia. Diabetes 1987, 36, 592–596. [CrossRef] [PubMed]

70. Starke, A.; Imamura, T.; Unger, R.H. Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. J. Clin. Investig. 1987, 79, 20–24. [CrossRef] [PubMed]

71. Kreymann, B.; Williams, G.; Ghatei, M.A.; Bloom, S.R. Glucagon-like peptide-1 7-36: A physiological incretin.” Mol. Endocrinol. 2000, 14, 122–129. [CrossRef] [PubMed]

72. Thorens, B. Neural regulation of pancreatic islet cell mass and function. Diabetes Obes. Metab. 2014, 16, 82–95. [CrossRef] [PubMed]

73. Lamy, C.M.; Sanno, H.; Labouebe, G.; Picard, A.; Magnan, C.; Chatton, J.Y.; Thorens, B. Somatostatin—Both hormone and neurotransmitter? Diabetologia 2012, 55, 3262–3272. [CrossRef] [PubMed]

74. Thorens, B. Brain glucose sensing and neural regulation of insulin and glucagon secretion. Diabetes Obes. Metab. 2011, 13 (Suppl. 1), 82–88. [CrossRef] [PubMed]

75. Hall, G.; van Hall, G.; Hansen, C.P.; Storkholm, J.H.; et al. Evidence of extrapancreatic glucagon secretion in man. Diabetes 2016, 65, 585–597. [CrossRef] [PubMed]

76. Bajouranas, D.R.; Fortner, J.G.; Jaspan, J.; Sherwin, R.S. Total pancreatectomy increases the metabolic response to glucagon in humans. J. Clin. Investig. 1986, 78, 439–446. [CrossRef] [PubMed]

77. Cryer, P.E. Hypoglycemia: Still the limiting factor in the glycemic management of diabetes. Endocr. Pract. 2008, 14, 750–756. [CrossRef] [PubMed]

78. Cryer, P.E. Hypoglycemia: Still the limiting factor in the glycemic management of diabetes. Endocr. Pract. 2008, 14, 750–756. [CrossRef] [PubMed]

79. Brereton, M.F.; Vergari, E.; Zhang, Q.; Clark, A. Alpha-, delta- and pp-cells: Are they the architectural cornerstones of islet structure and co-ordination? J. Histochem. Cytochem. 2015, 63, 575–591. [CrossRef] [PubMed]

80. Briant, L.; Salehi, A.; Vergari, E.; Zhang, Q.; Rorsman, P. Glucagon secretion from pancreatic alpha-cells. Ups. J. Med. Sci. 2016, 121, 113–119. [CrossRef] [PubMed]

81. Bajorunas, D.R.; Fortner, J.G.; Jaspan, J.; Sherwin, R.S. Total pancreatectomy increases the metabolic response to glucagon in humans. J. Clin. Investig. 1986, 78, 439–446. [CrossRef] [PubMed]

82. Yasui, K. Effects of total pancreatectomy on the secretion of gut glucagon in humans. Jpn. J. Surg. 1983, 13, 122–129. [CrossRef] [PubMed]

83. Lund, A.; Bagger, J.I.; Wever Albrechtsen, N.J.; Christensen, M.; Grondahl, M.; Hartmann, B.; Mathiesen, E.R.; Hansen, C.P.; Storkholm, J.H.; van Hall, G.; et al. Evidence of extrapancreatic glucagon secretion in man. Diabetes 2016, 65, 585–597. [CrossRef] [PubMed]

84. Schuit, F.; Van Lommel, L.; Granvik, M.; Goyvaerts, L.; de Faudier, G.; Schraenen, A.; Lemaire, K. Beta-cell-specific gene repression: A mechanism to protect against inappropriate or maladjusted insulin secretion? Diabetes 2012, 61, 969–975. [CrossRef] [PubMed]

85. Pullen, T.J.; da Silva Xavier, G.; Kelsey, G.; Rutter, G.A. Mir-29a and mir-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (MCT1). Mol. Cell. Biol. 2011, 31, 3182–3194. [CrossRef] [PubMed]

86. Pullen, T.J.; Khan, A.M.; Barton, G.; Butcher, S.A.; Sun, G.; Rutter, G.A. Identification of genes selectively disallowed in the pancreatic islet. Islets 2010, 2, 89–95. [CrossRef] [PubMed]

87. Martinez-Sanchez, A.; Nguyen-Tu, M.S.; Rutter, G.A. Dicer inactivation identifies pancreatic beta-cell “disallowed” genes targeted by micrornas. Mol. Endocrinol. 2015, 29, 1067–1079. [CrossRef] [PubMed]
88. Dooley, J.; Garcia-Perez, J.E.; Sreenivasan, J.; Schlenner, S.M.; Vangoisenhoven, R.; Papadopoulou, A.S.; Tian, L.; Schonefeldt, S.; Sermeels, L.; Deroose, C.; et al. The mircoRNA-29 family dictates the balance between homeostatic and pathological glucose handling in diabetes and obesity. *Diabetes* 2016, 65, 53–61. [CrossRef] [PubMed]

89. Bagge, A.; Clausen, T.R.; Larsen, S.; Ladefoged, M.; Rosenstierne, M.W.; Larsen, L.; Vang, O.; Nielsen, J.H.; Dalgaard, L.T. Microrna-29a is up-regulated in beta-cells by glucose and decreases glucose-stimulated insulin secretion. *Biochem. Biophys. Res. Commun.* 2012, 426, 266–272. [CrossRef] [PubMed]

90. Dalgaard, L.T.; Eliasson, L. An ‘alpha-beta’ of pancreatic islet microribonucleotides. *Int. J. Biochem. Cell Biol.* 2017, 88, 208–219. [CrossRef] [PubMed]

91. Eliasson, L.; Esguerra, J.L. Role of non-coding rnas in pancreatic beta-cell development and physiology. *Acta Physiol.* 2014, 211, 273–284. [CrossRef] [PubMed]

92. Esguerra, J.L.; Bolmeson, C.; Cilio, C.M.; Eliasson, L. Differential glucose-regulation of micrornas in pancreatic islets of non-obese type 2 diabetes model goto-kakizaki rat. *PLoS ONE* 2011, 6, e18613. [CrossRef] [PubMed]

93. Esguerra, J.L.; Eliasson, L. Functional implications of long non-coding RNAs in the pancreatic islets of langerhans. *Front. Genet.* 2014, 5, 209. [CrossRef] [PubMed]

94. Kalis, M.; Bolmeson, C.; Esguerra, J.L.; Gupta, S.; Edlund, A.; Tormo-Badia, N.; Speidel, D.; Holmberg, D.; Mayans, S.; Khoo, N.K.; et al. Beta-cell specific deletion of dicer1 leads to defective insulin secretion and diabetes mellitus. *PLoS ONE* 2011, 6, e29166. [CrossRef] [PubMed]

95. Poy, M.N.; Eliasson, L.; Krutzfeldt, J.; Kuwajima, S.; Ma, X.; Macdonald, P.E.; Pfeffer, S.; Tuschi, T.; Rajewsky, N.; Rorsman, P.; et al. A pancreatic islet-specific microrna regulates insulin secretion. *Nature* 2004, 432, 226–230. [CrossRef] [PubMed]

96. Osmai, M.; Osmai, Y.; Bang-Berthelsen, C.H.; Pallesen, E.M.; Vestergaard, A.L.; Novotny, G.W.; Pociot, F.; Mandrup-Poulsen, T. Micrornas as regulators of beta-cell function and dysfunction. *Diabetes Metab. Res. Rev.* 2016, 32, 334–349. [CrossRef] [PubMed]

97. Guay, C.; Regazzi, R. Micrornas and the functional beta cell mass: For better or worse. *Diabetes Metab.* 2015, 41, 369–377. [CrossRef] [PubMed]

98. Kameswaran, V.; Kaestner, K.H. The missing Lnc(RNA) between the pancreatic beta-cell and diabetes. *Diabetes Metab.* 2016, 42, 226–230. [CrossRef] [PubMed]

99. Van de Bunt, M.; Gaulton, K.J.; Parts, L.; Moran, I.; Johnson, P.R.; Lindgren, C.M.; Ferrer, J.; Gloyn, A.L.; McCarthy, M.I. The mirna profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis. *PLoS ONE* 2013, 8, e55272. [CrossRef] [PubMed]

100. Klein, D.; Misawa, R.; Bravo-Egana, V.; Vargas, N.; Rosero, S.; Piroso, J.; Ichii, H.; Umland, O.; Zhijie, J.; Tsinoremas, N.; et al. Microrna expression in alpha and beta cells of human pancreatic islets. *PLoS ONE* 2013, 8, e55064. [CrossRef] [PubMed]

101. Poy, M.N.; Hauser, J.; Trajkovski, M.; Braun, M.; Collins, S.; Rorsman, P.; Zavolan, M.; Stoffel, M. Mir-375 maintains normal pancreatic alpha- and beta-cell mass. *Proc. Natl. Acad. Sci. USA* 2009, 106, 5813–5818. [CrossRef] [PubMed]

102. Latreille, M.; Herrmanns, K.; Renwick, N.; Tschl, T.; Malecki, M.T.; McCarthy, M.I.; Owen, K.R.; Rulicke, T.; Stoffel, M. Mir-375 gene dosage in pancreatic beta-cells: Implications for regulation of beta-cell mass and biomarker development. *J. Mol. Med.* 2015, 93, 1159–1169. [CrossRef] [PubMed]

103. Babagallo, D.; Piro, S.; Condorelli, A.G.; Mascali, L.G.; Usano, E.; Parrinello, N.; Monello, A.; Statello, L.; Ragusa, M.; Rauzuvino, A.M.; et al. miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic alpha cells to cytokine-induced apoptosis as compared to beta cells. *BMC Genom.* 2013, 14, 62. [CrossRef] [PubMed]

104. Mohan, R.; Mao, Y.; Zhang, S.; Zhang, Y.W.; Xu, C.R.; Gradwohl, G.; Tang, X. Differentially expressed microRNA-483 confers distinct functions in pancreatic beta- and alpha-cells. *J. Biol. Chem.* 2015, 290, 19955–19966. [CrossRef] [PubMed]

105. Dhawan, S.; Georgias, S.; Tschien, S.I.; Fan, G.; Bhushan, A. Pancreatic beta cell identity is maintained by DNA methylation-mediated repression of arx. *Dev. Cell* 2011, 20, 419–429. [CrossRef] [PubMed]

106. Rorsman, P.; Ashcroft, F.M. Pancreatic beta-cell electrical activity and insulin secretion: Of mice and men. *Physiol. Rev.* 2018, 98, 117–214. [CrossRef] [PubMed]
107. Chen, C.; Cohrs, C.M.; Stertmann, J.; Bozsak, R.; Speier, S. Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis. *Mol. Metab.* **2017**, *6*, 943–957. [CrossRef] [PubMed]

108. Avrahami, D.; Wang, Y.J.; Klochendler, A.; Dor, Y.; Glaser, B.; Kaestner, K.H. Beta-cells are not uniform after all-新颖的insights into molecular heterogeneity of insulin-secreting cells. *Diabetes Obes. Metab.* **2017**, *19* (Suppl. 1), 147–152. [CrossRef] [PubMed]

109. Lacey, R.J.; Berrow, N.S.; London, N.J.; Lake, S.P.; James, R.F.; Scarpello, J.H.; Morgan, N.G. Differential association signals at this locus. *Mol. Genet. Metab.* **2012**, *104*, 147–152. [CrossRef] [PubMed]

110. Rutter, G.A.; Pullen, T.J.; Hodson, D.J.; Martinez-Sanchez, A. Pancreatic beta-cell identity, glucose sensing and the control of insulin secretion. *Biochem. J.* **2015**, *466*, 203–218. [CrossRef] [PubMed]

111. Kanno, T.; Gopel, S.O.; Rorsman, P.; Wakui, M. Cellular function in multicellular system for hormone-secretion: Electrophysiological aspect of studies on alpha-, beta- and delta-cells of the pancreatic islet. *Neurosci. Res.* **2002**, *42*, 79–90. [CrossRef]

112. Huang, L.; Shen, H.; Atkinson, M.A.; Kennedy, R.T. Detection of exocytosis at individual pancreatic beta cells by amperometry at a chemically modified microelectrode. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 9608–9612. [CrossRef] [PubMed]

113. Rorsman, P.; Renstrom, E. Insulin granule dynamics in pancreatic beta cells. *J. Clin. Investig.* **1990**, *85*, 598–609. [CrossRef] [PubMed]

114. Irwin, N.; Flatt, P.R. Enteroregulatory hormone mimetics for the treatment of obesity and diabetes. *Curr. Opin. Pharmacol.* **2013**, *13*, 989–995. [CrossRef] [PubMed]

115. Ensinck, J.W.; Laschansky, E.C.; Vogel, R.E.; Simonowitz, D.A.; Roos, B.A.; Francis, B.H. Circulating prosomatostatin-derived peptides. Differential responses to food ingestion. *J. Clin. Investig.* **1989**, *83*, 1580–1589. [CrossRef] [PubMed]

116. Kailey, B.; van de Bunt, M.; Cheley, S.; Johnson, P.R.; MacDonald, P.E.; Gloyn, A.L.; Rorsman, P.; Braun, M. Sstr2 is the functionally dominant somatostatin receptor in human pancreatic beta- and alpha-cells. *Am. J. Physiol. Endocrinol. Metab.* **2012**, *303*, E1107–E1116. [CrossRef] [PubMed]

117. Lacey, R.J.; Berrow, N.S.; London, N.J.; Lake, S.P.; James, R.F.; Scarpetto, J.H.; Morgan, N.G. Differential effects of beta-adrenergic agonists on insulin secretion from pancreatic islets isolated from rat and man. *J. Mol. Endocrinol.* **1990**, *5*, 49–54. [CrossRef] [PubMed]

118. Renstrom, E.; Ding, W.G.; Bokvist, K.; Rorsman, P. Neurotransmitter-induced inhibition of exocytosis in insulin-secreting beta cells by activation of calcineurin. *Neuron* **1996**, *17*, 513–522. [CrossRef]

119. Wierup, N.; Sundler, F.; Heller, R.S. The islet ghrelin cell. *J. Mol. Endocrinol.* **2014**, *52*, R35–R49. [CrossRef] [PubMed]

120. Seufert, J.; Kieffer, T.J.; Leech, C.A.; Holz, G.G.; Moritz, W.; Ricordi, C.; Habener, J.F. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus. *J. Clin. Endocrinol. Metab.* **1999**, *84*, 670–676. [CrossRef] [PubMed]

121. Ferrer, R.; Soria, B.; Dawson, C.M.; Atwater, I.; Rojas, E. Effects of Zn\textsuperscript{2+} on glucose-induced electrical activity and insulin release from mouse pancreatic islets. *Am. J. Physiol.* **1984**, *246*, C520–C527. [CrossRef] [PubMed]

122. Thorens, B. GLUT2, glucose sensing and glucose homeostasis. *Diabetologia* **2015**, *58*, 221–232. [CrossRef] [PubMed]

123. Heimberg, H.; De Vos, A.; Pipeleers, D.; Thorens, B.; Schuit, F. Differences in glucose transporter gene expression between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport but not in glucose utilization. *J. Biol. Chem.* **1995**, *270*, 8971–8975. [CrossRef] [PubMed]

124. McCulloch, L.J.; van de Bunt, M.; Braun, M.; Frayn, K.N.; Clark, A.; Gloyn, A.L. GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: Implications for understanding genetic association signals at this locus. *Mol. Genet. Metab.* **2011**, *104*, 648–653. [CrossRef] [PubMed]

125. Ahren, B. Autonomic regulation of islet hormone secretion—Implications for health and disease. *Diabetologia* **2000**, *43*, 393–410. [CrossRef] [PubMed]

126. Bonner, C.; Kerr-Conte, J.; Gmyr, V.; Queniat, G.; Moerman, E.; Thevenet, J.; Beaucamps, C.; Delalleau, N.; Popescu, I.; Malaisse, W.; et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. *Nat. Med.* **2015**, *21*, 512–517. [CrossRef] [PubMed]
127. Doliba, N.M.; Qin, W.; Najafi, H.; Liu, C.; Buettger, C.W.; Sotiris, J.; Collins, H.W.; Li, C.; Stanley, C.A.; Wilson, D.F.; et al. Glucokinase activation repairs defective bioenergetics of islets of langerhans isolated from type 2 diabetics. *Am. J. Physiol. Endocrinol. Metab.* 2012, 302, E87–E102. [CrossRef] [PubMed]

128. Thorrez, L.; Laudadio, I.; Van Deun, K.; Quintens, R.; Hendrickx, N.; Granvik, M.; Lemaire, K.; Schraenen, A.; Van Lommel, L.; Lehnert, S.; et al. Tissue-specific disallowance of housekeeping genes: The other face of cell differentiation. *Genome Res.* 2011, 21, 95–105. [CrossRef] [PubMed]

129. Del Guerra, S.; Lupi, R.; Marselli, L.; Masini, M.; Bugliani, M.; Sbrana, S.; Torri, S.; Pollera, M.; Boggi, U.; Mosca, F.; et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. *Diabetes* 2005, 54, 727–735. [CrossRef] [PubMed]

130. Anello, M.; Lupi, R.; Spampinato, D.; Piro, S.; Masini, M.; Boggi, U.; Del Prato, S.; Rabuazzo, A.M.; Purrello, F.; Marchetti, P. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. *Diabetologia* 2008, 45, 282–289. [CrossRef] [PubMed]

131. Menge, B.A.; Breuer, T.G.; Ritter, P.R.; Uhl, W.; Schmidt, W.E.; Meier, J.J. Long-term recovery of beta-cell function after partial pancreatectomy in humans. *Metabolism* 2011, 60, 620–624. [CrossRef] [PubMed]

132. Menge, B.A.; Tannapfel, A.; Belyaev, O.; Drescher, R.; Muller, C.; Uhl, W.; Schmidt, W.E.; Meier, J.J. Partial pancreatectomy in adult humans does not provoke beta-cell regeneration. *Diabetes* 2008, 57, 142–149. [CrossRef] [PubMed]

133. Ferrannini, E.; Natali, A.; Bell, P.; Cavallo-Perin, P.; Lalic, N.; Mingrone, G. Insulin resistance and hypersecretion in obesity. European group for the study of insulin resistance (EGIR). *J. Clin. Invest.* 1997, 100, 1166–1173. [CrossRef] [PubMed]

134. Seltzer, H.S.; Allen, E.W.; Herron, A.L., Jr.; Brennan, M.T. Insulin secretion in response to glycemic stimulus: Relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. *J. Clin. Invest.* 1967, 46, 323–335. [CrossRef] [PubMed]

135. Lillioja, S.; Mott, D.M.; Spraul, M.; Ferraro, R.; Foley, J.E.; Ravussin, E.; Knowler, W.C.; Bennett, P.H.; Bogardus, C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of pima indians. *N. Engl. J. Med.* 1993, 329, 1988–1992. [CrossRef] [PubMed]

136. Camastra, S.; Manco, M.; Mari, A.; Baldi, S.; Gastaldelli, A.; Greco, A.V.; Mingrone, G.; Ferrannini, E. Beta-cell function in morbidly obese subjects during free living: Long-term effects of weight loss. *Diabetes* 2005, 54, 2382–2389. [CrossRef] [PubMed]

137. Polonsky, K.S.; Given, B.D.; Van Cauter, E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. *J. Clin. Invest.* 1988, 81, 442–448. [CrossRef] [PubMed]

138. Perley, M.; Kipnis, D.M. Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects. *Diabetes* 1966, 15, 867–874. [CrossRef] [PubMed]

139. Mezghenna, K.; Qin, W.; Najafi, H.; Liu, C.; Buettger, C.W.; Sotiris, J.; Collins, H.W.; Li, C.; Stanley, C.A.; Wilson, D.F.; et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in korea. *J. Clin. Endocrinol. Metab.* 2003, 88, 2300–2308. [CrossRef] [PubMed]

140. Hanley, S.C.; Austin, E.; Assouline-Thomas, B.; Kapeluto, J.; Blachman, J.; Moosavi, M.; Petropanovski,M.; Rosenberg, L. β-cell mass dynamics and islet cell plasticity in human type 2 diabetes. *Endocrinology* 2010, 151, 1462–1472. [CrossRef] [PubMed]

141. Yoon, K.H.; Ko, S.H.; Cho, J.H.; Lee, J.M.; Ahn, Y.B.; Song, K.H.; Yoo, S.J.; Kang, M.I.; Cha, B.Y.; Lee, K.W.; et al. Increased neuronal nitric oxide synthase dimerisation is involved in rat and human pancreatic beta cell hyperactivity in obesity. *Diabetologia* 2011, 54, 2856–2866. [CrossRef] [PubMed]

142. Marchetti, P.; Petit, P.; et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus. *Diabetes Care* 2013, 36, 111–117. [CrossRef] [PubMed]
Braun, M.; Ramracheya, R.; Amisten, S.; Bengtsson, M.; Moritoh, Y.; Zhang, Q.; Johnson, P.R.; Rorsman, P.

Grill, V.; Efendic, S. Abnormal d cell secretion in alloxan-diabetes: Influence by drug and aberrant metabolism.

Grill, V.; Gutniak, M.; Roovete, A.; Efendic, S. A stimulating effect of glucose on somatostatin release is.

Gromada, J.; Hoy, M.; Buschard, K.; Salehi, A.; Rorsman, P. Somatostatin inhibits exocytosis in rat pancreatic.

Hokfelt, T.; Efendic, S.; Hellerstrom, C.; Johansson, O.; Luft, R.; Arimura, A. Cellular localization of somatostatin in endocrine-like cells and neurons of the rat with special references to the a1-cells of the pancreatic islets and to the hypothalamus. Acta Endocrinol. Suppl. 1975, 200, 5–41. [CrossRef]

Hokfelt, T.; Johansson, O.; Efendic, S.; Luft, R.; Arimura, A. Are there somatostatin-containing nerves in the rat gut? Immunohistochemical evidence for a new type of peripheral nerves. Experientia 1975, 31, 852–854. [CrossRef]

Hauge-Evans, A.C.; King, A.J.; Carmignac, D.; Richardson, C.C.; Robinson, I.C.; Low, M.J.; Christie, M.R.; Persaud, S.J.; Jones, P.M. Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 2009, 58, 403–411. [CrossRef] [PubMed]

Hokfelt, T., Efendic, S., Hellerstrom, C., Johansson, O., Luft, R., Arimura, A. Are there somatostatin-containing nerves in the rat gut? Immunohistochemical evidence for a new type of peripheral nerves. Experientia 1975, 31, 852–854. [CrossRef] [PubMed]

Arimura, A.; Sato, H.; Dupont, A.; Nishi, N.; Schally, A.V. Somatostatin: Abundance of immunoreactive hormone in rat stomach and pancreas. Science 1975, 189, 1007–1009. [CrossRef] [PubMed]

Hauge-Evans, A.C.; King, A.J.; Carmignac, D.; Richardson, C.C.; Robinson, I.C.; Low, M.J.; Christie, M.R.; Persaud, S.J.; Jones, P.M. Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 2009, 58, 403–411. [CrossRef] [PubMed]

Berts, A.; Ball, A.; Dryselius, G.; Gylfe, E.; Heilman, B. Glucose stimulation of somatostatin-producing islet cells involves oscillatory Ca\(^{2+}\) signaling. Endocrinology 1996, 137, 693–697. [CrossRef] [PubMed]

Braun, M.; Ramacheya, R.; Amisten, S.; Bengtsson, M.; Moritoh, Y.; Zhang, Q.; Johnson, P.R.; Rorsman, P. Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic delta cells. Diabetologia 2007, 50, 1566–1578. [CrossRef] [PubMed]

Grill, V.; Efendic, S. Stimulation by calcium and barium of somatostatin release. Evidence for lower sensitivity of D-vis-a-vis B- and A-cells. Acta Physiol. Scand. 1984, 122, 401–407. [CrossRef] [PubMed]

Grill, V.; Efendic, S. Abnormal d cell secretion in alloxan-diabetes: Influence by drug and aberrant metabolism. Am. J. Physiol. 1984, 246, E483–E492. [CrossRef] [PubMed]

Grill, V.; Gutniak, M.; Roovete, A.; Efendic, S. A stimulating effect of glucose on somatostatin release is impaired in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1984, 59, 293–297. [CrossRef] [PubMed]
164. Marcinkiewicz, M.; Ramla, D.; Seidah, N.G.; Chretien, M. Developmental expression of the prohormone convertases PCI and PC2 in mouse pancreatic islets. *Endocrinology* **1994**, *135*, 1651–1660. [CrossRef] [PubMed]

165. Francis, B.H.; Baskin, D.G.; Saunders, D.R.; Ensinck, J.W. Distribution of somatostatin-14 and somatostatin-28 gastrointestinal-pancreatic cells of rats and humans. *Gastroenterology* **1990**, *99*, 1283–1291. [CrossRef]

166. Kumar, U.; Sasi, R.; Suresh, S.; Patel, A.; Thangaraju, M.; Metrakos, P.; Patel, S.C.; Patel, Y.C. Subtype-selective expression of the five somatostatin receptors (HSSTR1–5) in human pancreatic islet cells: A quantitative double-label immunohistochemical analysis. *Diabetes* **1999**, *48*, 77–85. [CrossRef] [PubMed]

167. Patel, Y.C.; Srikant, C.B. Somatostatin receptors. *Trends Endocrinol. Metab.* **1997**, *8*, 398–405. [CrossRef]

168. Kreienkamp, H.J.; Honck, H.H.; Richter, D. Coupling of rat somatostatin receptor subtypes to a g-protein gated inwardly rectifying potassium channel (GIRK1). *FEBS Lett.* **1997**, *419*, 92–94. [CrossRef]

169. Collombat, P.; Hecksher-Sorensen, J.; Serup, P.; Mansouri, A. Specifying pancreatic endocrine cell fates. *Mech. Dev.* **2006**, *123*, 501–512. [CrossRef] [PubMed]

170. Zhang, J.; McKenna, L.B.; Bogue, C.W.; Kaestner, K.H. The diabetes gene hhex maintains delta-cell differentiation and islet function. *Genes Dev.* **2014**, *28*, 829–834. [CrossRef] [PubMed]

171. Guardado Mendoza, R.; Perego, C.; Finzi, G.; La Rosa, S.; Capella, C.; Jimenez-Ceja, L.M.; Velloso, L.A.; Saad, M.J.; Sessa, F.; Bertuzzi, F.; et al. Delta cell death in the islet of langerhans and the progression from normal glucose tolerance to type 2 diabetes in non-human primates (baboon, papio hamadryas). *Diabetologia* **2015**, *58*, 1814–1826. [CrossRef] [PubMed]

172. Larsson, L.I.; Sundler, F.; Hakanson, R.; Pollock, H.G.; Kimmel, J.R. Localization of app, a postulated new hormone, to a pancreatic endocrine cell type. *Histochemistry* **1974**, *42*, 377–382. [CrossRef] [PubMed]

173. Larsson, L.I.; Sundler, F.; Hakanson, R. Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cells. *Cell Tissue Res.* **1975**, *156*, 167–171. [CrossRef] [PubMed]

174. Larsson, L.I.; Sundler, F.; Hakanson, R. Pancreatic polypeptide—A postulated new hormone: Identification of its cellular storage site by light and electron microscopic immunocytochemistry. *Diabetologia* **1976**, *12*, 211–226. [CrossRef] [PubMed]

175. Ekblad, E.; Sundler, F. Distribution of pancreatic polypeptide and peptide YY. *Peptides* **2002**, *23*, 251–261. [CrossRef]

176. Solcia, E.; Fiocca, R.; Capella, C.; Usellini, L.; Sessa, F.; Rindi, G.; Schwartz, T.W.; Yanaihara, N. Glucagon- and PP-related peptides of intestinal L cells and pancreatic/gastric A or Pp cells. Possible interrelationships of peptides and cells during evolution, fetal development and tumor growth. *Peptides* **1985**, *6* (Suppl. 3), 223–229. [CrossRef]

177. Clark, A.; Wells, C.A.; Buley, I.D.; Cruickshank, J.K.; Vanhegan, R.I.; Matthews, D.R.; Cooper, G.J.; Holman, R.R.; Turner, R.C. Islet amyloid, increased a-cells, reduced b-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes. *Diabetes Res.* **1988**, *9*, 151–159. [PubMed]

178. Stefan, Y.; Orci, L.; Malaisse-Lagae, F.; Perrelet, A.; Patol, Y.; Unger, R.H. Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. *Diabetes* **1982**, *31*, 694–700. [CrossRef] [PubMed]

179. Sundler, F.; Hakanson, R.; Larsson, L.I. Ontogeny of rat pancreatic polypeptide (PP) cells. *Cell Tissue Res.* **1977**, *178*, 303–306. [CrossRef] [PubMed]

180. Rahier, J.; Wallon, J.; Looszen, S.; Lefevere, A.; Gepts, W.; Haot, J. The pancreatic polypeptide cells in the human pancreas: The effects of age and diabetes. *J. Clin. Endocrinol. Metab.* **1983**, *56*, 441–444. [CrossRef] [PubMed]

181. Stefan, Y.; Grasso, S.; Perrelet, A.; Orci, L. The pancreatic polypeptide-rich lobe of the human pancreas: Definitive identification of its derivation from the ventral pancreatic primordium. *Diabetologia* **1982**, *23*, 141–142. [CrossRef] [PubMed]

182. Holzer, P.; Reichmann, F.; Farzi, A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. *Neuropeptides* **2012**, *46*, 261–274. [CrossRef] [PubMed]

183. Field, B.C.; Chaudhri, O.B.; Bloom, S.R. Bowels control brain: Gut hormones and obesity. *Nat. Rev. Endocrinol.* **2010**, *6*, 444–453. [CrossRef] [PubMed]

184. Schwartz, T.W. Pancreatic polypeptide: A hormone under vagal control. *Gastroenterology* **1983**, *85*, 1411–1425. [PubMed]

185. Schwartz, T.W. Pancreatic polypeptide: A unique model for vagal control of endocrine systems. *J. Auton. Nerv. Syst.* **1983**, *9*, 99–111. [CrossRef]

186. Weir, G.C.; Samols, E.; Loo, S.; Patel, Y.C.; Gabbay, K.H. Somatostatin and pancreatic polypeptide secretion: Effects of glucagon, insulin, and arginine. *Diabetes* **1979**, *28*, 35–40. [CrossRef] [PubMed]
208. Broglio, F.; Arvat, E.; Benso, A.; Gottero, C.; Muccioli, G.; Papotti, M.; van der Lely, A.J.; Deghenghi, R.; Ghigo, E. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J. Clin. Endocrinol. Metab. 2001, 86, 5083-5086. [CrossRef] [PubMed]

209. Broglio, F.; Gottero, C.; Benso, A.; Prodam, F.; Desteefanis, S.; Gauna, C.; Maccario, M.; Deghenghi, R.; van der Lely, A.J.; Ghigo, E. Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J. Clin. Endocrinol. Metab. 2003, 88, 4268-4272. [CrossRef] [PubMed]

210. Egido, E.M.; Rodriguez-Gallardo, J.; Silvestre, R.A.; Marco, J. Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur. J. Endocrinol. 2002, 146, 241-244. [CrossRef] [PubMed]

211. Colombo, M.; Gregersen, S.; Xiao, J.; Hermansen, K. Effects of ghrelin and other neuropeptides (CART, MCH, orexin A and B, and GLP-1) on the release of insulin from isolated rat islets. Pancreas 2003, 27, 161-166. [CrossRef] [PubMed]

212. Reimer, M.K.; Pacini, G.; Ahren, B. Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology 2003, 144, 916-921. [CrossRef] [PubMed]

213. Wierup, N.; Sundler, F. Circulating levels of ghrelin in human fetuses. Eur. J. Endocrinol. 2004, 150, 405. [CrossRef] [PubMed]

214. Salehi, A.; Dornonville de la Cour, C.; Hakanson, R.; Lundquist, I. Effects of ghrelin on insulin and glucagon secretion: A study of isolated pancreatic islets and intact mice. Regul. Pept. 2004, 118, 143-150. [CrossRef] [PubMed]

215. Arosio, M.; Ronchi, C.L.; Gebbia, C.; Cappiello, V.; Beck-Peccoz, P.; Peracchi, M. Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels. J. Clin. Endocrinol. Metab. 2003, 88, 701-704. [CrossRef] [PubMed]

© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).